APC and Sepsis: Specifically, the mutations that minimise anticoagulation produced variants that have equivalent or sometimes even greater beneficial effects than wild-type recombinant APC, as demonstrated in animal models of stroke [100,101,102,103,104,105], traumatic brain injury [106], amyotropic lateral sclerosis [107], endotoxaemia and sepsis mortality [108,109,110], myocardial and liver ischaemic/reperfusion injury [111,112,113], and Pseudomonas aeruginosa pneumonia [114].